var myjson = [{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','author':'Gary Nachman','authorID':263,'ticker':'LCI-NYSE','company':'Lannett','companyID':1785,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-12T21:55:28.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'9f68f93f080482a40fc7dcd5e96d326e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'a67e5f6446f7fe4f500af1b228a330dd','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'b3534f5045e68842d8ceeb9946ee8e98','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d41d8cd98f00b204e9800998ecf8427e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'e08341ebedc9cfebbb1fe78e4717eb0e','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'fb61878451d81f7c5deb11dde460e4de','title':'Adjusting Model After Taking a Step Forward in 3Q','author':'Gary Nachman','authorID':263,'ticker':'VRX-NYSE','company':'Valeant Pharmaceuticals','companyID':1422,'sector':'Specialty Pharmaceuticals','sectorID':91,'publication':'2017-11-13T00:27:16.00','category':'comments','country':'United States'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'d7f4d70cae5e27fcf012e38e5864fb20','title':'Spin-Off Ahead of Schedule','author':'Richard Carlson','authorID':48,'ticker':'DLPH-NYSE','company':'Delphi','companyID':1670,'sector':'Autos/Mobility Equipment & Technology','sectorID':205,'publication':'2017-11-13T21:51:13.00','category':'flashes','country':'United Kingdom'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0417c9b9148aedf5d492cfde948086f8','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0aba19b0590f7ca23df4fec66a51ebf1','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'0cc175b9c0f1b6a831c399e269772661','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'3b2b25c10c856e85b1dc1685d8667de2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'50181f7ddd6a89b2404c3b9ec8ccedc0','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'5f2de58b2acaa274c14961ee1837555f','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'618755e457b4ba61e4f6f4287c8a20b2','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'690ee062782400f67c39dc631ae76e32','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'81fbc1c01369bdd803683c82a0fe6b1a','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'88f422f15062901b41d60eb5988c62d7','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'902dff8ba0654ad59ec30e175b3f848b','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'},{'email':'9cdaf6e5104160d4b3333bc55ba12385','title':'Q3 Earnings Below Our Estimate','author':'Jonathan Lamers','authorID':150,'ticker':'HLF-TSX','company':'High Liner Foods','companyID':1663,'sector':'Special Situations','sectorID':92,'publication':'2017-11-14T05:46:58.00','category':'comments','country':'Canada'}]